Ear, Nose, Throat & Oral Health • ICD-10-CM T14.8XXA
Human bite - accidental
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM T14.8XXA • 8 Linked .gov / PubMed Citations
•
Governance: Dr. Elena Vance, MD, FACE (NPI #1043218901)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Human bite - accidental Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as T14.8XXA, Human bite - accidental falls under ENT & Hearing management, where hearing protection/amplification [Human bite - accidental T14.8XXA] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Human bite - accidental uses ICD-10 T14.8XXA across ENT & Hearing specialty care.
- 3 Typical cash cost range: Differential triage of Human bite - accidental (T14.8XXA) utilizes hearing protection/amplification [Human bite - accidental T14.8XXA].
- 4 Top reported side effects / signs: Objective lab/clinical target for Human bite - accidental: Periodontal Pocket Depth in Human bite - accidental (T14.8XXA: & Bleeding Index) (Probing <= 3 mm without bleeding (T14.8XXA)) and Pure-Tone Audiometry & in Human bite - accidental (T14.8XXA: Tympanometry).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Human bite - accidental
What Is Human bite - accidental?
Designated in federal medical registries as T14.8XXA, Human bite - accidental falls under ENT & Hearing management, where hearing protection/amplification [Human bite - accidental T14.8XXA] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Human bite - accidental (ICD-10 T14.8XXA) is driven by or subgingival bacterial in Human bite - accidental (T14.8XXA: biofilm triggering periodontal); specialists in Ear, Nose, Throat & Oral Health monitor Pure-Tone Audiometry & in Human bite - accidental (T14.8XXA: Tympanometry) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Human bite - accidental (T14.8XXA): bleeding or receding in Human bite - accidental (T14.8XXA: gums, tooth sensitivity,)
- • Secondary Human bite - accidental clinical sign: muffled hearing, ear in Human bite - accidental (T14.8XXA: fullness, popping pressure,)
- • Symptom flares in Human bite - accidental correlating with Periodontal Pocket Depth in Human bite - accidental (T14.8XXA: & Bleeding Index) deviation outside Probing <= 3 mm without bleeding (T14.8XXA)
- • Functional ent & hearing impact requiring hearing protection/amplification [Human bite - accidental T14.8XXA] evaluation (T14.8XXA)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Human bite - accidental Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | T14.8XXA | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Ear, Nose, Throat & Oral Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Periodontal Pocket Depth in Human bite - accidental (T14.8XXA: & Bleeding Index) | Probing <= 3 mm without bleeding (T14.8XXA) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pure-Tone Audiometry & in Human bite - accidental (T14.8XXA: Tympanometry) | Thresholds <= 20 dB HL; normal middle-ear pressure (T14.8XXA) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Human bite - accidental
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Isentress (Raltegravir) Isentress • RxCUI 744846 | Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor | 74% | $33.7839 | $ 640.00 /mo |
| Bivigam (Immune Globulin Intravenous (Human) 10%) Bivigam • RxCUI RXN-B698006503 | Human Immunoglobulin G | 86% | $2.5300 | $ 190.66 /mo |
| Emtricitabine Emtriva • RxCUI 403875 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 92% | $17.4267 | $ 355.75 /mo |
| Ustekinumab-Ttwe Pyzchiva • RxCUI 2705557 | Interleukin-12 Antagonist | 81% | $4039.7780 | $ 185.00 /mo |
| Etravirine Intelence • RxCUI 754761 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor | 86% | $24.2549 | $ 94.56 /mo |
| Human Botulinum Neurotoxin A/B Immune Globulin Babybig • RxCUI 544491 | Human Immunoglobulin G | 84% | $2.3100 | $ 102.06 /mo |
| Pifeltro (Doravirine) Pifeltro • RxCUI 2055766 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor | 84% | $59.5992 | $ 640.00 /mo |
| Efgartigimod Alfa and Hyaluronidase (Human Recombinant) Vyvgart Hytrulo • RxCUI RXN-734753102-2449 | Neonatal Fc Receptor Blocker | 87% | $1.0400 | $ 50.62 /mo |
| Yeztugo (Lenacapavir Sodium) Yeztugo • RxCUI RXN-B619583401 | Human Immunodeficiency Virus 1 Capsid Inhibitor | 79% | $2.6000 | $ 195.70 /mo |
| Ziagen (Abacavir Sulfate) Ziagen • RxCUI 242679-B49702222 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 90% | $0.6247 | $ 15.52 /mo |
| Abacavir and Lamivudine Abacavir and Lamivudine Generic • RxCUI 602393 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | 75% | $1.2621 | $ 59.61 /mo |
| Omnitrope (Somatropin) Omnitrope • RxCUI RXN-B07813004 | Recombinant Human Growth Hormone | 75% | $855.3223 | $ 640.00 /mo |
| Optison (Human Albumin Microspheres and Perflutren) Optison • RxCUI RXN-B04072707 | Contrast Agent for Ultrasound Imaging | 74% | $2.1800 | $ 165.46 /mo |
| Thrombin Human and Fibrinogen Tachosil • RxCUI RXN-83078702-2829 | Human Blood Coagulation Factor | 84% | $0.9400 | $ 46.57 /mo |
| Pyzchiva (Ustekinumab-Ttwe) Pyzchiva • RxCUI 2705564 | Interleukin-12 Antagonist | 93% | $4039.7780 | $ 640.00 /mo |
| Lonapegsomatropin-Tcgd Skytrofa • RxCUI RXN-73362003-2261 | Recombinant Human Growth Hormone | 80% | $1.1000 | $ 53.05 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Human bite - accidental)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on [World Report] First human case of Shamonda virus Virologists say the wider risk to public health is low. The Lancet • 2026-10-31 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 97/100 | PMID LANCET-2806831375 ↗ |
| New Insights on Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized: What a 2,076-Participant Study Found These integrated analyses did not demonstrate any clinically meaningful impact from ADA occurring after treatment with eptinezumab. Frontiers in immunology • 2021-01-15 • Phase III Randomized Trial | N = 2,076 | 96/100 | PMID 34759933 ↗ |
| New Insights on A single intra-articular injection of JTA-004, a combination of human plasma,: What a 746-Participant Study Found A single IA injection of JTA-004 was not superior to a saline solution (LSmean difference: -1.50 mm, 95%CI 5.12; 2.12, p= 0.42) or Synvisc-One® (LSmean difference: 2.40, 95% CI: -1.22; 6.02, p=0.20) for the treatment of OA... Osteoarthritis and cartilage • 2026-02-15 • Phase III Randomized Trial | N = 746 | 93/100 | PMID 41015076 ↗ |
| New Insights on Real-world benefits and safety of SYN023 (Zamerovimab and Mazorelvimab: What a 750-Participant Study Found This study indicates that SYN023, a monoclonal antibody product, may be used as part of rabies post-exposure prophylaxis and provides superior protection sooner after exposure than HRIG. Vaccine • 2025-08-13 • Phase III Randomized Trial | N = 750 | 93/100 | PMID 40479926 ↗ |
| New Insights on [Effect of recombinant human thrombin for hemostasis in liver resection: a: What a 348-Participant Study Found Among them, 232 were in the thrombin group and 116 were in the placebo group, with balanced and comparable demographics and baseline characteristics between the two groups. Zhonghua yi xue za zhi • 2023-11-14 • Phase III Randomized Trial | N = 348 | 93/100 | PMID 37963740 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Human bite - accidental Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Human bite - accidental community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Human bite - accidental.